Clinical trial
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
NCT00005879 · University of Kansas Medical Center, Other · Completed
Key facts
| NCT number | NCT00005879 |
|---|---|
| Title | LY353381 in Preventing Breast Cancer in Women With Hyperplasia |
| Official title | A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia |
| Lead sponsor | University of Kansas Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | arzoxifene, Placebo |
| Enrollment | 199 |
| Start date | Aug 1, 2000 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | May 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: